CJC-1295 with DAC vs GHRP-6 (Growth Hormone Releasing Peptide-6)
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
A synthetic hexapeptide that signals your pituitary to release growth hormone through a unique pathway, with emerging evidence of heart-protective benefits.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
CJC-1295 with DAC
2–2 mg
GHRP-6 (Growth Hormone Releasing Peptide-6)
100–100 mcg
Frequency
CJC-1295 with DAC
Twice weekly
GHRP-6 (Growth Hormone Releasing Peptide-6)
Multiple times daily
Administration
CJC-1295 with DAC
Subcutaneous injection
GHRP-6 (Growth Hormone Releasing Peptide-6)
Subcutaneous injection
Cycle length
CJC-1295 with DAC
8-12 weeks
GHRP-6 (Growth Hormone Releasing Peptide-6)
8-12 weeks
Onset speed
CJC-1295 with DAC
Moderate (1-2 weeks)
GHRP-6 (Growth Hormone Releasing Peptide-6)
Moderate (1-2 weeks)
Evidence level
CJC-1295 with DAC
Moderate human trials (Phase 1-2)
GHRP-6 (Growth Hormone Releasing Peptide-6)
Limited human trials
Benefit ratings
GH Elevation
Convenience
Recovery Support
Muscle Recovery and Growth
Cellular Health and Protection
Appetite and Nutrient Intake
Compound specifications
CJC-1295 with DAC
Molecular formula
C165H269N47O46
Molecular weight
3647.28 g/mol
Half-life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS number
863288-34-0
GHRP-6 (Growth Hormone Releasing Peptide-6)
Molecular formula
C46H56N12O6
Molecular weight
873.0 g/mol
Half-life
~2.5 hours
Bioavailability
<1% oral, high subcutaneous
CAS number
87616-84-0
Dosing compared
CJC-1295 with DAC
Subcutaneous
1 mg (1000 mcg)
Once weekly · 2-4 weeks
A starting dose used in practice. The DAC version is long-acting (about a 6-8 day half-life), so weekly dosing keeps growth hormone and IGF-1 raised. In the Phase 1 trial a single dose raised GH for 6+ days and IGF-1 for up to 11 days. [2]
2 mg (2000 mcg)
Once weekly (or split twice weekly) · 8-12 weeks
The common maintenance dose, roughly in line with the 30-60 mcg/kg weekly range studied in the Phase 1 trial. [1][2] In the ascending-dose trials, single injections raised mean GH 2- to 10-fold for six or more days and IGF-I 1.5- to 3-fold for 9-11 days; 30 and 60 µg/kg doses were the best tolerated [2].
2 mg per dose
Twice weekly · 8-12 weeks
A higher total weekly amount split into two doses, used by experienced users; near the top of the 30-60 mcg/kg weekly range from the clinical study. [2]
GHRP-6 (Growth Hormone Releasing Peptide-6)
Subcutaneous
~100 mcg per injection (approx. 1 mcg/kg)
1-3 times daily, on an empty stomach · Open-ended in research practice
Research-practice GH-secretagogue dosing; the ~100 mcg anchor reflects the validated 1 mcg/kg GH-saturating dose, though no isolated subcutaneous human dose-response trial exists [6].
Intravenous
1 mcg/kg bolus (optionally followed by 1 mcg/kg/hr infusion)
Single bolus for acute GH testing; infusion studies ran up to ~34 hours · Acute test or infusion study
Trial-established near-maximal GH-releasing intravenous dose in healthy men; pituitary responsiveness maintained over prolonged infusion [6]. Dose-response in men: mean peak GH of 7.6, 16.5, and 68.7 µg/L at 0.1, 0.3, and 1.0 µg/kg respectively [7].
Best suited for
CJC-1295 with DAC
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
GHRP-6 (Growth Hormone Releasing Peptide-6)
Athletes and Serious Trainers
If you're hitting the gym hard and want better recovery and muscle growth, GHRP-6 amplifies your body's natural GH response. This is particularly valuable during intense training phases when you want to maximize adaptation and minimize soreness. The appetite stimulation also helps you consume the calories you need to grow.
Those Exploring Novel Peptide Protocols
GHRP-6 offers a unique mechanism through the ghrelin receptor, making it valuable for users who want to explore diverse GH-stimulation pathways. It works distinctly from GHRH-based approaches and pairs well with other GH secretagogues for synergistic effects.
Longevity and Metabolic Health Enthusiasts
Growth hormone plays roles in metabolic health, body composition, and potentially aging markers. GHRP-6's emerging research on cellular protection and antioxidant activation makes it interesting for those interested in broader health optimization beyond just muscle growth.
Side effects
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
GHRP-6 (Growth Hormone Releasing Peptide-6)
Common
- Increased Appetite
- Mild Joint or Muscle Discomfort
- Water Retention or Mild Swelling
Uncommon
- Sleep Disturbances
- Mild Dizziness or Lightheadedness
Serious
- Allergic Reaction
Safety & evidence
CJC-1295 with DAC
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- Active cancer or history of malignancy
- Pregnancy or breastfeeding
- Pituitary tumors or disorders
- Diabetic retinopathy
- Uncontrolled diabetes
GHRP-6 (Growth Hormone Releasing Peptide-6)
Evidence level
Limited human trials
FDA status
Research compound
Safety overview
GHRP-6 has a relatively long research history dating back to 1981, with human studies demonstrating its ability to stimulate GH release. The good news is that animal safety studies show excellent tolerability at high doses, and the side effects reported are generally mild and reversible. However, it's not FDA-approved, so use is based on research evidence rather than pharmaceutical oversight. Always purchase from reputable sources and consider medical consultation, especially if you have existing health conditions.
Contraindications
- Known allergy or sensitivity to any component of the peptide
- Active cancer or history of cancer without medical clearance
- Severe cardiovascular disease or uncontrolled hypertension
- Acute critical illness or sepsis
Which is right for you?
Choose CJC-1295 with DAC if...
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity
Choose GHRP-6 (Growth Hormone Releasing Peptide-6) if...
- Building lean muscle mass and improving body composition
- Recovery from intense training programs and athletic performance
- Supporting overall metabolic health and longevity markers
- Exploring novel GH-stimulation pathways for those who respond well to peptide protocols